VCIM
ANTX icon

Velan Capital Investment Management’s AN2 Therapeutics ANTX Stock Holding History

Velan Capital Investment Management’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$194K Buy
+40,000
New +$172K 0.12% 41

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Velan Capital Investment Management's ANTX Position: Q2 2026 in Review

Velan Capital Investment Management opened a new position in AN2 Therapeutics (ANTX) in Q2 2026: 40,000 shares worth $194K. The stake represents 0.12% of the portfolio and ranks #41 among its holdings.

66 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

  • Velan Capital Investment Management held 40,000 shares of AN2 Therapeutics worth $194K as of Q2 2026.
  • AN2 Therapeutics was a new Velan Capital Investment Management position in Q2 2026.
  • AN2 Therapeutics made up 0.12% of Velan Capital Investment Management's portfolio in Q2 2026, its #41 holding.
  • 66 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on Velan Capital Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.